Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 18, 2024
Emerging Company Profile
Adaptin: Bispecifics hitchhike into the brain using edited T cells
Duke spinout has new method to get T cell engagers across the blood-brain barrier
BioCentury | Aug 25, 2023
Finance
Aug. 25 Quick Takes: RayzeBio, Neumora prepare for IPOs
Plus: Akeso’s bispecific gets priority review in China, and updates on Merck-Eisai, Sandoz’s Tysabri biosimilar and the IRA
BioCentury | Aug 26, 2022
Discovery & Translation
Detecting Parkinson’s via breathing signals; plus Antisense, Noster and more
BioCentury’s roundup of translational news
BioCentury | Aug 21, 2021
Targets & Mechanisms
Next-generation multiple sclerosis therapies look beyond B cells
Early-stage approaches aim for more precise immune suppression, remyelination
BioCentury | Jun 5, 2021
Targets & Mechanisms
Going beyond genetic medicines for muscular dystrophy
Muscular dystrophy programs in the clinic cover not only a range of muscle mechanisms but also anti-fibrotic and anti-inflammation ones
BioCentury | Jan 30, 2021
Regulation
Novartis subcutaneous mAb for MS, Incyte and Karyopharm oral cancer therapies backed by CHMP
Among the therapies to receive a positive opinion from EMA’s CHMP in January were drugs from Novartis, Incyte and Karyopharm that have convenient routes of administration. The agency
BioCentury | Aug 28, 2020
Deals
BARDA enlisting start-ups in fight against COVID-19 via JLABS collaboration
JLABS funneling start-up innovation to BARDA via Blue Knight initiative
BioCentury | Oct 25, 2019
Product Development
Deciding factors in the shifting MS treatment landscape
The new drugs in MS show injectables can compete with orals. The next compounds will test that further
BioCentury | Sep 19, 2019
Product Development
Anokion puts liver to the test
Anokion’s preclinical data showcase induction of immune tolerance via liver-targeted autoantigens
BioCentury | Feb 9, 2018
Clinical News
Biogen discontinuing natalizumab for stroke after Phase IIb miss
Items per page:
1 - 10 of 86